Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
NWBO > SEC Filings for NWBO > Form 8-K on 13-Mar-2014All Recent SEC Filings

Show all filings for NORTHWEST BIOTHERAPEUTICS INC

Form 8-K for NORTHWEST BIOTHERAPEUTICS INC


13-Mar-2014

Other Events, Financial Statements and Exhibits


Item 8.01. Other Events.

On March 7, 2014, Northwest Biotherapeutics, Inc. issued a press release, in response to shareholder inquiries, reporting that it had received a recommendation from the independent Data Safety Monitoring Board that the Company's Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer should continue as planned, based on an analysis of safety data. Analysis of the efficacy data is still outstanding. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K.

On March 10, 2014, Northwest Biotherapeutics, Inc. issued a press release announcing that (i) the German regulatory authority has approved a "Hospital Exemption" early access program with DCVax-L for all glioma brain cancers, including the most severe grade (Glioblastoma multiforme, Grade IV) and lower grade (less malignant) gliomas, both newly diagnosed and recurrent; and (ii) the German reimbursement authority has determined that DCVax-L treatments for glioma brain cancers are eligible for negotiating and obtaining reimbursement from the Sickness Funds of the German healthcare system. A copy of the press release is included as Exhibit 99.2 to this Current Report on Form 8-K.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release of Northwest Biotherapeutics, Inc. dated March 7, 2014.

99.2 Press Release of Northwest Biotherapeutics, Inc. dated March 10, 2014.

  Add NWBO to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for NWBO - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.